Department of Urology (Shou JZ),Department of Radiation Oncology (Others),Cancer Hospital and Institute,National Cancer Center/National Clinical Research Center for Cancer,Chinese Academy of Medical Sciences and Peking Union Medical College,100021 Beijing.
Objective To analyze the efficacy and its impacting factors of pelvic confined muscle invasive bladder cancer (MIBC) treated with radiotherapy,also including the preservation of functional bladders and the treatment related late toxicity. Methods Forty-five MIBC patients who received radiotherapy from March 1999 to October 2016 in our hospital were analyzed.41 of the patients were transitional cell carcinomas. The radiation volume included the bladder±pelvic lymph node with or without local tumor boost,with a median bladder dose of 45 Gy and median tumor dose of 56 Gy.24 patients received concurrent chemoradiotherapy.14 patients received neoadjuvant chemotherapy,and 29 underwent transurethral resection of bladder tumors before radiotherapy. Results The median follow-up duration was 28 months (range,4–101 months).The 3-year overall survival were 51%.Concurrent chemoradiotherapy had a better survival than that of radiation alone,with 3-year overall survival of 64% and 30%(P=0.001).The effect of neoadjuvant chemotherapy on 3-year overall survival was not obvious,59% and 47%(P=0.540) with or without neoadjuvant chemotherapy. The 3-year overall survival were 58% and 43%(P=0.160),respectively for patients with or without the transurethral resection of bladder tumors. The 3-year overall survival were 20% and 79%(P=0.001) for patients with or without relapse. Nine patients recurred locally and fourteen patients developed metastases. The highest bowel toxicity of more than 3 months after radiotherapy was grade 2 in 2 patients. Late grade 2 urinary toxicity occurred in 4 patients,grade 3 in 2 patients. All other patients preserved their functional bladders except 7 patients who had an uncontrolled bladder tumors or radiation induced severe injury of bladder function. Conclusions A better survival could be obtained for localized muscle invasive bladder cancer treated with concurrent chemoradiotherapy. Most of the patients can preserve their functional bladders after radiotherapy,and the late toxicity is acceptable.
Gao Junjun,Liu Yueping,Shou Jianzhong et al. The efficacy of radiotherapy for muscle invasive bladder cancer and its associated factors analysis[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 740-743.
[1] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China.2015[J].Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Chang SS,Bochner BH,Chou R,et al. Treatment of non-metastatic muscle-invasive bladder cancer:AUA/ASCO/ASTRO/SUO Gui-deline[J].J Urology,2017,198(3):552-559.DOI:10.1016/j.juro.2017.04.086.
[3] Flaig TW,Spiess PE,Agarwal N,et al. National comprehensive cancer network.bladder cancer (version 3.2018)[M/OL][2018-06-18].http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.2018,V3.
[4] Ploussard G,Daneshmand S,Efstathiou JA,et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer:a systematic review[J].Eur Urol,2014,66(1):120-137.DOI:10.1016/j.eururo.2014.02.038.
[5] Clark PE,Spiess PE,Agarwal N,et al. National Comprehensive Cancer Network. Bladder Cancer (Version 2.2016) M/OL][2018-06-18].http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf,2016,V2.
[6] Mak RH,Zietman AL,Heney NM,et al. Bladder preservation:optimizing radiotherapy and integrated treatment strategies[J].BJU international,2008,102(9 pt B):1345-1353.DOI:10.1111/j.1464-410x.2008.07981.x.
[7] Arcangeli G,Arcangeli S,Strigari L.A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)[J].Crit Rev Oncol Hematol,2015,94(1):105-115.DOI:10.1016/j.critrevonc.2014.11.007.
[8] Hafeez S,Horwich A,Omar O,et al. Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder[J].Br J Cancer,2016,114(12):e24.DOI:10.1038/bjc.2016.132.
[9] Alfred Witjes J,Lebret T,Comperat EM,et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J].Eur Urol,2017,71(3):462-475.DOI:10.1016/j.eururo.2016.06.020.
[10] Malmstr m PU.Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis[J].Scand J Urol Nephrol Suppl,1988,112:1-55.
[11] Mak RH,Hunt D,Shipley WU,et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy:a pooled analysis of Radiation Therapy Oncology Group protocols 8802,8903,9506,9706,9906,and 0233[J].J Clin Oncol,2014,32(34):3801-3809.DOI:10.1200/JCO.2014.57.5548.
[12] James ND,Hussain SA,Hall E,et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer[J].N Engl J Med,2012,366(4):1477-1488.DOI:10.1056/NEJMc 1206002.
[13] Coppin CM,Gospodarowicz MK,James K,et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1996,14(11):2901-2907.DOI:10.1200/JCO.1996.14.11.2901.
[14] Shipley WU,Prout GR,Einstein AB Jr., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery[J].JAMA,1987,258(7):931-935.
[15] Pisters LL,Westney L.The management of locally recurrent invasive bladder cancer following radical cystectomy[J].Semin Urol Oncol,1996,14(2):112-119.
[16] Griffiths G,Hall R,Sylvester R,et al. International phase Ⅲ trial assessing neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer:long-term results of the BA06 30894 trial[J].J Clin Oncol,2011,29(16):2171-2177.DOI:10.1200/JCO.2010.32.3139.
[17] Neoadjuvant chemotherapy in invasive bladder cancer:update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration[J].Eur Urol,2005,48(2):202-205,205-206.
[18] Giacalone NJ,Shipley WU,Clayman RH,et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer:an updated analysis of the massachusetts general hospital experience[J].Eur Urol,2017,72(3):e64-e65.DOI:10.1016/j.eururo.2017.06.007.
[19] Efstathiou JA,Spiegel DY,Shipley WU,et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer:the MGH experience[J].Eur Urol,2012,62(2):705-711.DOI:10.1016/j.eururo.2012.04.054.
2018, Vol. 27 
